An interventional study of 'Double tap' balloon post-dilation in Aortic Stenosis and TAVI(Transcatheter Aortic Valve Implantation), sponsored by The Alfred. Not yet recruiting at 3 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by The Alfred · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Aortic Valve Stenosis with a site in Australia — 10 open to participants now, 15 under way, none of them phase 3. Aortic Valve Stenosis · Australia.
Among the 35 studies in Aortic Valve Stenosis with a site in Australia, this one is the 17th largest by planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2026, is one of 28 with no phase, reaches primary completion later than 11 of the 14 other live ones, and was the 34th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →10 of the 35 studies in Aortic Valve Stenosis with a site in Australia are open now. Recruiting first, the newest first:
EnCompass Technologies, Inc. · Sites in Australia, United States
Ages 21–90
World Health Research Inc. · Sites in Australia, Canada, Colombia and 5 more countries
Transverse Medical, Inc. · Sites in Australia
Ages 18+
Abbott Medical Devices · Sites in Australia, France, Germany and 8 more countries
Ages 18–100
Edwards Lifesciences · Sites in Australia, United States, Canada and 1 more country
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 250 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 358 across the 28 interventional studies, 1,032 across the 7 observational. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 35 have an industry lead sponsor. The 10 most frequent:
The Alfred is the lead sponsor of 47 studies on the registry; 4 are open to participants now.
The Alfred has 2 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Aortic Valve Stenosis with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06689839EnCompass Technologies, Inc.Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR | 2026-12 |
| NCT06991517World Health Research Inc.A Study of Transcatheter Aortic Valve Replacement Case Selection and Valve Sizing Using the ABC Bicuspid Sizing Algorithm | 2026-12 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT05172960Edwards LifesciencesALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve | 2027-07 |
| NCT06008080Abbott Medical DevicesPost-Market Clinical Follow Up Study With Navitor Valve | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 35 studies in Aortic Valve Stenosis with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to discover if routine 'double tap' balloon post-dilation improves valve expansion and clinical outcomes in adults undergoing Transcatheter Aortic Valve Implantation (TAVI) with the SAPIEN balloon-expandable TAVI prosthesis.
The primary hypothesis is that routine 'double tap' balloon post-dilation improves TAVI valve expansion. The secondary hypothesis is that routine 'double tap' balloon post-dilation improves TAVI valve haemodynamic performance.
Participants will be randomised to balloon-expandable TAVI either with or without routine 'double tap' balloon post-dilation.
The ACE-DOUBLE trial will be a multicentre, registry nested, block randomized, open label clinical trial comparing routine versus discretionary balloon post-dilation strategies following TAVI using the SAPIEN 3 balloon-expandable THV for severe aortic stenosis (AS).
Patients with severe symptomatic aortic valve disease that are accepted for TAVI using a balloon-expandable THV. Currently, the only balloon-expandable THV in routine clinical practice in Australia are the Sapien 3 Ultra and Sapien 3 Ultra Resilia (Edwards Lifesciences, Irvine CA, USA). Patients will be recruited from three TAVI centres participating in the ACE registry: The Alfred Hospital, Cabrini Hospital and Epworth Hospital are all located in Melbourne, Australia.
Specific sub-groups may benefit more from balloon post-dilation (BPD), and hence exploratory analyses will be performed to examine the effect of BPD on primary endpoints in the following subgroups:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in the routine deployment arm will have no further post-dilation after satisfactory initial deployment of the balloon-expandable THV
Participants in the double tap arm will undergo a second inflation of the delivery system balloon at the same filll volume after satisfactory initial deployment of the balloon-expandable THV
Other: 'Double tap' balloon post-dilation
Routine second inflation of the valve delivery balloon ('double-tap') BPD following balloon-expandable valve TAVI
Fluoroscopic valve expansion
Percentage (%) final valve expansion measured by fluoroscopy
Time frame: Day 1 post-procedure
Haemodynamic performance
Echocardiographic transvalvular mean pressure gradient (mmHg)
Time frame: Day 1-3 post-procedure
Haemodynamic performance
Echocardiographic aortic valve area (cmsq)
Time frame: Day 1-3 post-procedure
Freedom from cardiovascular death or valve reintervention
Freedom from occurrence of composite of cardiovascular death or valve reintervention
Time frame: 1 year and 3 years post-procedure
CT sub-study: final valve expansion measured by non-contrast computed tomography
CT sub-study: final valve expansion (%) measured by non-contrast computed tomography
Time frame: 30-90 days post-procedure
New permanent pacemaker implantation
New permanent pacemaker implantation
Time frame: 30 days post-procedure
Stroke
Confirmed stroke
Time frame: 30 days post-procedure
Plan to share: No — Individual participant data cannot be released without specific approval from the HREC committee.
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Apr 2028, 24 months later.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 24 months is below that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Alfred